Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial
Open accessAbstract
Importance: Individuals with Down syndrome (DS) are at high risk of developing Alzheimer disease due to an increased dose of the amyloid precursor protein gene, APP, which leads to increased levels of full-length APP and its products, including amyloid-β (Aβ). The liposome-based antiamyloid ACI-24 vaccine is intended to treat neurological disorders caused by misfolded Aβ pathological protein. However, the safety, tolerability, and immunogenicity of the ACI-24 vaccine among adults with DS have not been fully examined. Objective: To assess the safety and tolerability of the ACI-24 vaccine among adults with DS as well as its ability to induce immunogenicity measured by anti-Aβ immunoglobulin G titers. Design, Setting, and Participants: This multicenter double-blind placebo-controlled dose-escalation phase 1b randomized clinical trial was conducted at 3 US academic medical centers with affiliated Down syndrome clinics between March 30, 2016, and June 29, 2020. A total of 20 adults with DS were screened; of those, 16 adults were eligible to participate. Eligibility criteria included men or women aged 25 to 45 years with cytogenetic diagnosis of either trisomy 21 or complete unbalanced translocation of chromosome 21. Between April 27, 2016, and July 2, 2018, participants were randomized 3:1 into 2 dose-level cohorts (8 participants per cohort, with 6 participants receiving the ACI-24 vaccine and 2 receiving placebo) in a 96-week study. Participants received 48 weeks of treatment followed by an additional 48 weeks of safety follow-up. Interventions: Participants were randomized to receive 7 subcutaneous injections of ACI-24, 300 μg or 1000 μg, or placebo. Main Outcomes and Measures: Primary outcomes were measures of safety and tolerability as well as antibody titers. Results: Among 16 enrolled participants, the mean (SD) age was 32.6 (4.4) years; 9 participants were women, and 7 were men. All participants were White, and 1 participant had Hispanic or Latino ethnicity. Treatment adherence was 100%. There were no cases of meningoencephalitis, death, or other serious adverse events (AEs) and no withdrawals as a result of AEs. Most treatment-emergent AEs were of mild intensity (110 of 132 events [83.3%]) and unrelated or unlikely to be related to the ACI-24 vaccine (113 of 132 events [85.6%]). No amyloid-related imaging abnormalities with edema or cerebral microhemorrhage and no evidence of central nervous system inflammation were observed on magnetic resonance imaging scans. Increases in anti-Aβ immunoglobulin G titers were observed in 4 of 12 participants (33.3%) receiving ACI-24 (2 receiving 300 μg and 2 receiving 1000 μg) compared with 0 participants receiving placebo. In addition, a greater increase was observed in plasma Aβ1-40 and Aβ1-42 levels among individuals receiving ACI-24. Conclusions and Relevance: In this study, the ACI-24 vaccine was safe and well tolerated in adults with DS. Evidence of immunogenicity along with pharmacodynamic and target engagement were observed, and anti-Aβ antibody titers were not associated with any adverse findings. These results support progression to clinical trials using an optimized formulation of the ACI-24 vaccine among individuals with DS. Trial Registration: ClinicalTrials.gov Identifier: NCT02738450.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The most common aspects of Alzheimer's disease involve accumulation of beta-amyloid plaques, tau proteins, and neuroinflammation; these are the main targets for candidate anti-Alzheimer vaccines.
“The most common aspects of AD involve the accumulation of beta-amyloid plaques, tau proteins, and neuroinflammation; these are the main targets for candidate anti-Alzheimer vaccines [48,49,50].”
From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [49]
Cites
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,010 · see citing works
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589 · see citing works
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · see citing works
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519 · see citing works
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · see citing works
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964 · see citing works
Self-citationLemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · see citing works
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383 · see citing works
Mann, D. M. A., Yates, P. O., & Marcyniuk, B. (1984) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1984.tb00351.x · Cited by 345 · see citing works
Fortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernández, S., Altuna, M., Pegueroles, J., Montal, V., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30689-9 · Cited by 340 · see citing works
Estimation of the number of people with Down syndrome in the United States
de Graaf, G., Buckley, F., & Skotko, B. G. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.127 · Cited by 338 · see citing works
Self-citationPresence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome
Teller, J. K., Russo, C., DeBusk, L. M., Angelini, G., Zaccheo, D., Dagna-Bricarelli, F., Scartezzini, P., Bertolini, S., Mann, D. M. A., Tabaton, M., et al. (1996) · Nature Medicine · doi:10.1038/nm0196-93 · Cited by 326 · see citing works
A prospective 20‐year longitudinal follow‐up of dementia in persons with Down syndrome
McCarron, M., McCallion, P., Reilly, E., Dunne, P., Carroll, R., & Mulryan, N. (2017) · Journal of Intellectual Disability Research · doi:10.1111/jir.12390 · Cited by 295 · see citing works
Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP
Doran, E., Keator, D., Head, E., Phelan, M. J., Kim, R., Totoiu, M., Barrio, J. R., Small, G. W., Potkin, S. G., & Lott, I. T. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160836 · Cited by 244 · see citing works
Alzheimer disease and Down syndrome: factors in pathogenesis
Lott, I. T., & Head, E. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.005 · Cited by 212 · see citing works
Estimation of the number of people with Down syndrome in Europe
de Graaf, G., Buckley, F., & Skotko, B. G. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-00748-y · Cited by 193 · see citing works
Self-citationThe pattern of amyloid accumulation in the brains of adults with Down syndrome
Annus, T., Wilson, L. R., Hong, Y. T., Acosta‐Cabronero, J., Fryer, T. D., Cárdenas‐Blanco, A., Smith, R. V., Boros, I., Coles, J., Aigbirhio, F. I., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.07.490 · Cited by 182 · see citing works
Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., der Auwera, I. V., LEUVEN, F. V., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 176 · see citing works
Self-citationAssociation of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
Hithersay, R., Startin, C. M., Hamburg, S., Mok, K. Y., Hardy, J., Fisher, E. M. C., Tybulewicz, V. L. J., Nizetic, D., & Strydom, A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3616 · Cited by 176 · see citing works
THE TOPOGRAPHY OF PLAQUES AND TANGLES IN DOWN'S SYNDROME PATIENTS OF DIFFERENT AGES
Mann, D. M. A., Yates, P. O., Marcyniuk, B., & Ravindra, C. (1986) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1986.tb00053.x · Cited by 161 · see citing works
Alzheimer's disease in Down syndrome: an overlooked population for prevention trials
Strydom, A., Coppus, A., Blesa, R., Danek, A., Fortea, J., Hardy, J., Levin, J., Nuebling, G., Rebillat, A., Ritchie, C., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.006 · Cited by 110 · see citing works
Rafii, M. S., Lukic, A. S., Andrews, R. D., Brewer, J. B., Rissman, R. A., Strother, S. C., Wernick, M. N., Pennington, C., Mobley, W. C., Ness, S. L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170390 · Cited by 95 · see citing works
Self-citationRafii, M. S., Wishnek, H., Brewer, J. B., Donohue, M., Ness, S. L., Mobley, W. C., Aisen, P. S. S., & Rissman, R. A. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00239 · Cited by 84 · see citing works
Self-citationHickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 83 · see citing works
Self-citationPihlgren, M., Silva, A. B., Madani, R., Giriens, V., Waeckerle‐Men, Y., Fettelschoss‐Gabriel, A., Hickman, D. T., López-Deber, M. P., Ndao, D. M., Vukicevic, M., et al. (2012) · Blood · doi:10.1182/blood-2012-02-413831 · Cited by 44 · see citing works
Self-citationAn Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome
Belichenko, P., Madani, R., Rey-Bellet, L., Pihlgren, M., Becker, A., Plassard, A., Vuillermot, S., Giriens, V., Nosheny, R., Kleschevnikov, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152471 · Cited by 35 · see citing works
Self-citationConti, E., Galimberti, G., Piazza, F., Raggi, M. E., & Ferrarese, C. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181aba63a · Cited by 28 · see citing works
Staunton, H., Trennery, C., Arbuckle, R., Guridi, M., Zhuravleva, E., Furlong, P., Fischer, R. A., & Hall, R. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01813-w · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Emerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381 · see citing works
Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125 · see citing works
Targeting aging and age-related diseases with vaccines
Wu, R., Sun, F., Zhang, W., Ren, J., & Liu, G.-H. (2024) · Nature Aging · doi:10.1038/s43587-024-00597-0 · Cited by 66 · see citing works
- Authors
- Rafii, M. S., Sol, O., Mobley, W. C., Delpretti, S., Skotko, B. G., Burke, A. D., Sabbagh, M. N., Yuan, S. H., Rissman, R. A., Pulsifer, M., Evans, C., Evans, A. C., Beth, G., Fournier, N., Gray, J. A., dos Santos, A. M., Hliva, V., Vukicevic, M., Kosco-Vilbois, M., Streffer, J., Pfeifer, A., & Feldman, H. H.
- Affiliations
- University of Southern California (US)
- AC Immune (Switzerland) (CH)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Barrow Neurological Institute (US)
- University of Minnesota (US)
- AC Immune SA, Lausanne, Switzerland
- Corresponding author
- Rafii, Michael S.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2022-06-01
- Volume
- 79
- Issue
- 6
- Pages
- 565
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC9086937
- OpenAlex
- W4229457728
- Cited by
- 52
- References
- 29
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 20 · 2023: 8 · 2022: 1
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (RF1AG073979, R01AG047922, R01AG073979, P30AG066530)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, Alzheimer's disease prevention, amyloid-beta, vaccine safety, tolerability, immunogenicity, dose escalation, adults with Down syndrome, dose-limiting adverse events, meningoencephalitis, neuroinflammation
- MeSH terms
- Adult, Alzheimer Disease, Double-Blind Method, Down Syndrome, Female, Humans, Immunoglobulin G, Male, Vaccines, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
